Related Experiment Video
Updated: Sep 21, 2025
13:51
Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
10.0K
Genomewide Association Study of Simvastatin Pharmacokinetics
Anssi J H Mykkänen1,2, Suvi Taskinen1,2, Mikko Neuvonen1,2
1Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Clinical Pharmacology and Therapeutics
|June 2, 2022
Summary
Genetic variations in SLCO1B1 and CYP3A4 significantly impact simvastatin drug levels. Understanding these genetic factors can help personalize simvastatin therapy for improved efficacy and safety.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Clinical Pharmacology
Background:
- Simvastatin pharmacokinetics exhibit inter-individual variability.
- Genetic factors are known to influence drug response and metabolism.
Purpose of the Study:
- To identify genetic determinants of single-dose simvastatin pharmacokinetics.
- To investigate the association of SLCO1B1 and CYP3A4 variants with simvastatin acid exposure.
Main Methods:
- Genome-wide association study (GWAS) and meta-analysis.
- Candidate gene analysis using stepwise linear regression.
- Genotype-phenotype correlation based on OATP1B1 and CYP3A4 function.
Main Results:
- SLCO1B1 c.521T>C variant strongly associated with simvastatin acid area under the concentration-time curve (AUC).
- CYP3A4 variants (e.g., CYP3A4*2) and other SLCO1B1 variants also showed significant associations with simvastatin acid AUC.
- Genotype-predicted OATP1B1 and CYP3A4 phenotypes significantly correlated with simvastatin acid exposure.
Conclusions:
- Genetic variants in SLCO1B1 and CYP3A4 are key determinants of simvastatin pharmacokinetics.
- Increased function SLCO1B1 variants and reduced function CYP3A4 variants may alter simvastatin efficacy and safety.
- Caution is advised when prescribing simvastatin to patients with decreased function SLCO1B1 or CYP3A4 alleles.
More Related Videos
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
14.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.4K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
90
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
90
00:54Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
206
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
206
01:12Analysis of Population Pharmacokinetic Data
403
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
403
01:10Pharmacokinetics: Overview
7.3K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
7.3K
01:09Hepatic Drug Clearance: Effect of Protein Binding
301
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
301